Our goal is to provide doctors with a tool to remove harmful components from the bloodstream to treat blood-borne diseases.

Keep In Touch

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £4M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood-borne diseases. The company’s initial targets are Sepsis, COVID-19, Leukaemia and Malaria. Located in the Translation and Innovation Hub in White City, the company is preparing for first-in-man trials in 2021.

Our multidisciplinary team has experience across various fields of science and technology development.

 

Job Posting: Quality Associate

Job Posting: Quality Associate
May 05, 2021

Job Title: Quality Associate Reports to:  Head of Engineering and Quality Start Date:  ASAP Hours of Work:  37.5 hours per week (full-time, 6-month probation) Salary:  £28-33k PA Closing Date:  End of December 2020 Please send your CV and a cover letter expl...
MediSieve selected for the London & Partners’ Business Growth Programme

MediSieve selected for the London & Partners’ Business Growth Programme
June 05, 2020

MediSieve was accepted onto the London & Partners’ Business Growth Programme! The free, three-month programme is giving London-based companies the tools they need to survive and thrive during these challenging times - from mentorship and account management, to expert advice and new business opportu...